Sensus Healthcare, Inc. shared topline results from a five-year retrospective study of non-melanoma skin cancer (NMSC) patients treated with Superficial Radiation Therapy (SRT). The study, which was conducted across four U.S. sites, showed a 98.9 percent cure rate among 516 male and female patients. These patients had a collective total of 776 NMSC lesions treated with Sensus' SRT-100.
Most patients in the study population were elderly with a mean age of 79 years. Kaplan-Meier estimates of cumulative recurrence rates of all tumors at both two and five years were 1.1 percent; basal cell carcinoma cumulative recurrence rates at five years were 1.2 percent, and squamous cell carcinoma cumulative recurrence rates were 0.9 percent.
"As we approach Skin Cancer Awareness Month in May, the results of this five-year study are not only timely and relevant but also show excellent cure rates," says Dr. William Roth, lead investigator of the study and Voluntary Clinical Professor at The University of Miami School of Medicine, Department of Dermatology, in a statement. "As the study confirms that SRT is a highly effective therapy, it's critical that this modality be available, especially to patients who have comorbidities or advancing age."
"SRT is a good option to offer patients with NMSC," adds Dr. Thomas Bender, dermatologist at Advanced Dermatology and Skin Care Centre, a Forefront Dermatology practice in Alabama. "We all have patients who aren't good candidates for surgery, and patients feel empowered when they can choose their own therapy as opposed to only having surgery to treat their skin cancer."
"These study results confirm what we've been hearing from our physicians," says Isabelle Raymond, PhD, Vice President, Clinical Development, Sensus Healthcare. "Sensus is committed to advancing research and development for optimal SRT treatment to improve patient outcomes, and we look forward to presenting detailed study results at an upcoming scientific meeting."